

UNITIED STAT. DEPARTMENT OF COMMERCE

Patent and Trasemark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SAH P.M

APPLICATION NUMBER FILING DATE FIRST NAMED APPLICANT ATTY, DOCKET NO. FARINA \mathbf{C} P30958C2 EXAMINER UM12/0717 EMMIN STUDY FERNANDEZ
SMATTECLINE BENCHAM CORPORATION PAPER NUMBER COMPUTE PATENTS U S UW2220 6 20% 1539 THE PT TRUCKIA PA 19406-0939 1711 DATE MAILED: 07/17/98 This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS **OFFICE ACTION SUMMARY** Responsive to communication(s) filed on This action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 D.C. 11, 453 O.G. 213. A shortened statutory period for response to this action is set to expire _ whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a). Disposition of Claims Claim(s) is/are pending in the application. Of the above, claim(s) is/are withdrawn from consideration. Claim(s) 1 - 8 is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction or election requirement. **Application Papers** See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed on _____is/are objected to by the Examiner. The proposed drawing correction, filed on ____ _is 🔲 approved 🔲 disapproved. The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received: Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) ☐ Notice of Reference Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). Interview Summary, PTO-413 Notice of Draftperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152

-SEE OFFICE ACTION ON THE FOLLOWING PAGES-

Serial No. 08/450,437

Art Unit 1711

All remaining rejections and/or objections follow.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claim 16 is rejected under 35 U.S.C. 102(e) as being anticipated by Shah (USP 5,434,158).

See the previous Office action at page 3 lines 3-5.

Claim 16 is rejected under 35 U.S.C. 102(e) as being anticipated by Chiang et al. (USP 5,607,936).

See the previous Office action at page 3 lines 8-9.

Applicants' arguments filed 5-7-98 have been fully considered but they are not deemed to be persuasive.

Applicants' certified translations have been reviewed.

However it is the position of the Examiner that with regard to claim 16, neither priority document supports this claim. Note for instance on page 1 of the translations which discloses only part of the subject matter of claim 16 in that neither priority document discloses that all the diseases recited in claim 16 are treated by administering to a mammal. Furthermore with regard to

Serial No. 08/450,437

Art Unit 1711

the earliest priority document, numerous disorders are missing from page 1 of the translation. It is therefore the position of the Examiner that the effective filing date of claim 16 is that of the U.S. filing date of the instant case. Applicants have informed the Office that they are considering filing an affidavit under 37 CFR 1.131 to overcome the rejection in view of Shah, however such an affidavit is ineffective in cases whereas in the instant case an application and a patent are claiming the same thing. Note claim 4 of Shah in this regard. Furthermore, claim 11 of Chiang et al. also claims the same subject matter as instant claim 16.

THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). The practice of automatically extending the shortened statutory period an additional month upon the filing of a timely first response to a final rejection has been discontinued by the Office. See 1021 TMOG 35.

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

Art Unit 1711

Any inquiry concerning this communication should be directed to Jeffrey Mullis at telephone number (703) 308-2820.

J. Mullis:cdc

July 13, 1998

JEFFREY C. MULLIS PRIMARY EXAMINER

GROUP 1200/